In this study, MSCs were used as carriers for a cell therapy strategy, utilizing their tumor‐homing characteristics that respond to TGF‐β to achieve controlled release of bioactive proteins (IL‐12 or nCD47‐SLAMF7) in the tumor microenvironment while avoiding systemic toxicity. Here, TGFB1 is linked to neoplasm.